GSK shows early promise in ovarian and womb cancer drug trial
The trial, which began in early 2023, involved a diverse group of participants across multiple sites. Preliminary data indicated that the drug demonstrated a significant reduction in tumor size for a substantial percentage of patients, suggesting its efficacy in combating these aggressive forms of cancer. For more details on how clinical trials work, visit this … Read more